Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs
04:40pm, Friday, 28'th Jul 2023
Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.
Biogen's Alzheimer's drug is the biggest growth catalyst for the stock, says Jefferies' Yee
03:27pm, Friday, 28'th Jul 2023
Michael Yee, Jefferies biotech analyst, joins 'Power Lunch' to discuss what Biogen's purchase of Reata means for the former, the biggest catalyst for Biogen stock, and more.
Why Biogen Agreed to Acquire Reata for $7.3 Billion
02:45pm, Friday, 28'th Jul 2023
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets.
Biogen to acquire Reata Pharmaceuticals for $7.3B
10:06am, Friday, 28'th Jul 2023
Biogen Inc (NASDAQ:BIIB) said it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion in cash as it bulks up its neuromuscular and rare disease portfolio. Shares of Reata shot up 52% to
Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
09:45am, Friday, 28'th Jul 2023
Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash.
08:02am, Friday, 28'th Jul 2023
Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
07:21am, Friday, 28'th Jul 2023
Biogen said it would buy biotech firm Reata Pharmaceuticals for roughly $6.5 billion to expand its presence in the rare disease drugs market.
Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash
07:16am, Friday, 28'th Jul 2023
Biogen Inc. BIIB, -0.93% said Friday it has agreed to acquire Reata Pharmaceuticals Inc. RETA, +2.32% for $7.3 billion in cash. Reata “has made significant advancements developing therapeutics that
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
06:00am, Thursday, 27'th Jul 2023
Biogen, facing declines in sales of older drugs, has a lot riding on its newly approved Alzheimer's disease treatment. The company recently announced moves to cut costs and favor investments in innova
Why Biogen Stock Got Sick Today
06:09pm, Tuesday, 25'th Jul 2023
The biotech delivered an estimates-beating second quarter. Sales and profitability were down on a year-over-year basis, though.
Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi launch
01:35pm, Tuesday, 25'th Jul 2023
Biogen said on Tuesday it expects to eliminate roughly 1,000 positions in the U.S. to save money ahead of launching a new drug to treat Alzheimer's disease.
Compared to Estimates, Biogen Inc. (BIIB) Q2 Earnings: A Look at Key Metrics
10:53am, Tuesday, 25'th Jul 2023
While the top- and bottom-line numbers for Biogen Inc. (BIIB) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compar
2023 Layoff Tracker: Biogen Cuts 1,000 Employees
10:15am, Tuesday, 25'th Jul 2023
Second quarter layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.
Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates
10:08am, Tuesday, 25'th Jul 2023
Biogen Inc. (BIIB) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $5.25 per share a year ago.
Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts
09:35am, Tuesday, 25'th Jul 2023
Biogen (NASDAQ: BIIB ) layoffs are on the way as the company seeks further profits with its new Alzheimer's disease drug launch. This has the pharmaceutical company planning to lay off 1,000 employees
